galantamine hydrobromide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 47 Diseases   10 Trials   10 Trials   1303 News 


«12...45678910111213141516»
  • ||||||||||  galantamine hydrobromide / Generic mfg.
    Review, Journal:  Biosynthesis and Biological Activities of Newly Discovered Amaryllidaceae Alkaloids. (Pubmed Central) -  Apr 1, 2021   
    AAs are specifically remarkable for their diverse pharmaceutical properties, as exemplified by the success of galantamine used to treat the symptoms of Alzheimer's disease. This review addresses the isolation, biological, and structure activity of AAs discovered from January 2015 to August 2020, supporting their therapeutic interest.
  • ||||||||||  galantamine hydrobromide / Generic mfg.
    Journal:  Evaluation of Pharmacological and Phytochemical Profiles Piptadeniastrum africanum (Hook.f.) Brenan Stem Bark Extracts. (Pubmed Central) -  Mar 30, 2021   
    Additionally, all extracts were able to contrast hydrogen peroxide-induced oxidative stress, in HypoE22 cells, thus restoring basal catecholamine and 3-hydroxykinurenine levels, whereas only methanol and water extracts stimulated basal dopamine release. Overall, data from the present study contribute to the biological assessment of P. africanum that appears to be a promising source of natural compounds with protective and neuromodulatory effects.
  • ||||||||||  galantamine hydrobromide / Generic mfg.
    Journal:  Loss of Basal Forebrain Cholinergic Neurons Following Adolescent Binge Ethanol Exposure: Recovery With the Cholinesterase Inhibitor Galantamine. (Pubmed Central) -  Mar 16, 2021   
    The finding of no AIE-induced changes in total basal forebrain NeuN + neurons with galantamine reversal of AIE-induced ChAT + neuron loss, TLR4/RAGE-pNF-κB p65 signals, and epigenetic transcription silencing markers suggests that AIE does not cause cell death, but rather the loss of the cholinergic phenotype. Together, these data suggest that AIE induces HMGB1-TLR4/RAGE-pNF-κB p65 signals, causing the loss of cholinergic phenotype (i.e., ChAT, TrkA, and p75) through epigenetic histone transcription silencing that result in the loss of the BFCN phenotype that can be prevented and restored by galantamine.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg.
    Biomarker, Journal:  Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer's disease. (Pubmed Central) -  Mar 13, 2021   
    Cholinergic dysfunction, demonstrated in the late 1970s and early 1980s, led to the introduction of acetylcholinesterase inhibitors (AChEIs) in 1993 (Tacrine) to enhance cholinergic neurotransmission as the first line of treatment against Alzheimer's disease (AD)...(i) The cholinergic system in AD, (ii) principles of AD PGx, (iii) PGx of Donepezil, Galantamine, Rivastigmine, Huperzine and other treatments, and (iv) practical recommendations...Defective variants may affect the clinical response to AChEIs. PGx geno-phenotyping is highly recommended prior to treatment.
  • ||||||||||  Journal:  Drugs for Parkinson's disease. (Pubmed Central) -  Mar 10, 2021   
    PGx geno-phenotyping is highly recommended prior to treatment. No abstract available
  • ||||||||||  galantamine hydrobromide / Generic mfg.
    Journal:  Concatemers to re-investigate the role of α5 in α4β2 nicotinic receptors. (Pubmed Central) -  Mar 2, 2021   
    Analysis of the α5-D398N mutation that is linked to smoking and lung cancer shows no significant effect on the electrophysiological function, suggesting that its effect might arise from alteration of other cellular processes. The concatemeric strategy provides a well-characterized platform for mechanistic analysis and screening of human α5-specific ligands.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg.
    Journal:  Therapeutic approaches to cholinergic deficiency in Lewy body diseases. (Pubmed Central) -  Feb 24, 2021   
    Targeting the basal forebrain with either deep brain stimulation (DBS) or cell-based therapies is another strategy to mitigate cortical cholinergic deficiency. Before NBM DBS studies continue, it will be important to resolve issues related to targeting, stimulation pattern, and duration.
  • ||||||||||  galantamine hydrobromide / Generic mfg., memantine / Generic mfg.
    Review, Journal:  Galantamine-Memantine combination in the treatment of Alzheimer's disease and beyond. (Pubmed Central) -  Feb 24, 2021   
    Although underutilized, the galantamine-memantine combination is the standard of care in the treatment of AD. Positive RCTs with the combination with concurrent improvement in symptoms and biomarkers may lead to FDA approval, which may lead to greater utilization of this combination in clinical practice.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg.
    Review, Journal:  Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Are Irreversible Inhibitors the Future? (Pubmed Central) -  Feb 13, 2021   
    Irreversible AChE inhibitors, with a long-acting mechanism of action, are inherently CNS selective and can more than double CNS AChE inhibition possible with short-acting inhibitors. Irreversible AChE inhibitors open the door to high-level CNS AChE inhibition and improved anti-neurodegenerative benefits that may be an important part of future treatments to more effectively prevent, delay the onset, or slow the progression of AD.
  • ||||||||||  galantamine hydrobromide / Generic mfg.
    Review, Journal:  Chemical and Biological Aspects of Montanine-Type Alkaloids Isolated from Plants of the Amaryllidaceae Family. (Pubmed Central) -  Feb 13, 2021   
    One of them, galantamine, is already used in the therapy of Alzheimer's disease as a long acting, selective, reversible inhibitor of acetylcholinesterase...Compared with other structural-types of AA, montanine-type alkaloids are predominantly present in plants in low concentrations, but some of them display promising biological properties, especially in vitro cytotoxic activity against different cancerous cell lines. The present review aims to summarize comprehensively the research that has been published on the Amaryllidaceae alkaloids of montanine-type.
  • ||||||||||  progesterone / Generic mfg., galantamine hydrobromide / Generic mfg.
    Preclinical, Journal:  SAR based in-vitro anticholinesterase and molecular docking studies of nitrogenous progesterone derivatives. (Pubmed Central) -  Feb 9, 2021   
    The cholinergic system plays an important role in the regulation of learning and memory processes and has been a major target for the design of anti-Alzheimer's drugs. Therefore, these nitrogen-containing progesterone derivatives will be of potential interest to researchers working in AD for developing new drugs or chemical tools to study the disease.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg.
    Journal:  Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer's Disease. (Pubmed Central) -  Feb 7, 2021   
    Individual ChEIs or dual-drug combinations were relatively non-toxic to neuronal cells, and only reduced cell viability at concentrations two-three orders of magnitude greater than that required to inhibit AChE. In summary, dual-drug combinations of ChEIs potentially represent a novel means of AD patient treatment, with reduced and more cost-effective drug dosing, and lowered likelihood of ADRs.
  • ||||||||||  galantamine hydrobromide / Generic mfg.
    Journal:  A Series of New Hydrazone Derivatives: Synthesis, Molecular Docking and Anticholinesterase Activity Studies. (Pubmed Central) -  Feb 3, 2021   
    These results, observed primarily at temporal recording sites overlying the auditory cortex, implicate α7 nAChRs in the enhancement of speech deviance detection and warrant further examination with respect to dysfunctional auditory deviance processing in individuals with SCZ. This study supports that novel hydrazone derivates may be used for the development of new BChE inhibitory agents.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., memantine / Generic mfg.
    Journal:  Amyloid Peptide Scaffolds Coordinate with Alzheimer's Disease Drugs. (Pubmed Central) -  Jan 26, 2021   
    The binding for some of the AD drugs is strong and stable even after extensive subsequent aqueous washings, denoting high capturing efficiency by the designed biomaterials, even after incubation at physiological conditions. Our findings constitute starting points to design drug delivery carriers binding to one or combinations of AD drugs (e.g. NMDA and Cholinesterase inhibitors).
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., memantine / Generic mfg.
    [VIRTUAL] Evaluation of Outpatient Dementia Medication Assessments at a Veterans Affairs Medical Center () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_858;    
    Collected data will be reviewed to evaluate if the Veteran had an appropriate provider and cognitive assessment within the past year. This data will help determine if there is a need for standardized monitoring of Veterans prescribed dementia medications at TVAMC.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., memantine / Generic mfg.
    Review, Journal:  Indian Medicinal Herbs and Formulations for Alzheimer's Disease, from Traditional Knowledge to Scientific Assessment. (Pubmed Central) -  Dec 17, 2020   
    In the present article, the experimental and clinical evidence have been reviewed for various Indian herbal medicines such as Centella asiatica, Bacopa monnieri, Curcuma longa, Clitoria ternatea, Withania somnifera, Celastrus paniculatus, Evolvulus alsinoides, Desmodium gangeticum, Eclipta alba, Moringa oleifera and Convolvulus pluricaulis, which have shown potential in cognitive impairment. Some commonly available herbal formulations for memory impairment in India have also been reviewed.
  • ||||||||||  Kinaction (masitinib) / AB Science
    Trial completion, Trial completion date, Trial primary completion date:  Masitinib in Patients With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) -  Dec 8, 2020   
    P3,  N=721, Completed, 
    2020; 81:XXX-XXX). Active, not recruiting --> Completed | Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  galantamine hydrobromide / Generic mfg.
    Preclinical, Journal:  The Regulation of AMPKα1/Nrf2/ HO-1 Pathway Mediated by Galantamine Hydrobromide Lycoremine in Myocardial Ischemia Reperfusion Rats (Pubmed Central) -  Nov 14, 2020   
    CHOP, cleaved Caspase-12, α-SMA, Collagen Ⅰ, AMPKα1, Nrf2, HO-1 protein levels were significantly reduced ( P<0.05), and GADD34 and BiP protein levels were significantly increased ( P<0.05) in Gal 2 mg/kg and Gal 4 mg/kg groups. The regulation of AMPKα1/Nrf2/HO-1 pathway mediated by Gal on endoplasmic reticulum stress apoptosis, myocardial apoptosis and fibrosis in myocardial ischemia reperfusion rats.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
    Journal:  Is Combining an Anticholinergic with a Cholinesterase Inhibitor a Good Strategy for High-Level CNS Cholinesterase Inhibition? (Pubmed Central) -  Nov 12, 2020   
    The currently approved cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) produce gastrointestinal toxicity which limits dosing to that which produces only about 25% to 35% CNS cholinesterase inhibition in Alzheimer's disease patients undergoing treatment, below the minimum therapeutic target of about 40% to 50% CNS inhibition considered necessary to treat cognitive impairment...Unfortunately, most common muscarinic anticholinergics, including solifenacin, readily penetrate the CNS and are directly associated with long-term exacerbation of the underlying neuropathology of Alzheimer's disease and increased brain atrophy...For long-term safety against accelerating the underlying disease processes in Alzheimer's disease, anticholinergics used to increase the tolerability of AChE inhibitors should not penetrate, or have very limited penetration, of the blood-brain barrier. Neurotrophic-mediated mechanisms by which cholinergic drugs may affect neurodegeneration in Alzheimer's disease are explored and improved treatment options are suggested.